Literature DB >> 16365192

Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation.

Carlos M Ferrario1.   

Abstract

This lecture summarizes the chronology and rationale that led to the discovery of angiotensin-(1-7) as a hormone that, in its own right, opposes the vasoconstrictor and proliferative actions of angiotensin II. The work discussed here additionally analyzes the newest findings on angiotensin-converting enzyme 2, the angiotensin-converting enzyme homologue that efficiently hydrolyzes angiotensin II into angiotensin-(1-7). Both components of this system may significantly influence our future perspective of the role of the renin-angiotensin system, not just in terms of its role in the regulation of cardiovascular and renal function but, moreover, as regulators of a vast array of disease processes in which inflammation and immune mechanisms play a role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365192     DOI: 10.1161/01.HYP.0000196268.08909.fb

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  83 in total

1.  Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide.

Authors:  Tanya M Gwathmey; Brian M Westwood; Nancy T Pirro; Lijun Tang; James C Rose; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

2.  ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension.

Authors:  Srinivas Sriramula; Jeffrey P Cardinale; Eric Lazartigues; Joseph Francis
Journal:  Cardiovasc Res       Date:  2011-09-27       Impact factor: 10.787

3.  Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system.

Authors:  Marc F Doobay; Lauren S Talman; Teresa D Obr; Xin Tian; Robin L Davisson; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-08-31       Impact factor: 3.619

4.  Titrating angiotensinogen in salt sensitive hypertension.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2007-04       Impact factor: 4.599

Review 5.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

Review 6.  Intratubular renin-angiotensin system in hypertension.

Authors:  L Gabriel Navar; Hiroyuki Kobori; Minolfa C Prieto; Romer A Gonzalez-Villalobos
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

7.  Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells.

Authors:  Lijie Cui; Kasem Nithipatikom; William B Campbell
Journal:  Anal Biochem       Date:  2007-07-05       Impact factor: 3.365

8.  Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives.

Authors:  C Qian; R G Schoemaker; W H van Gilst; B Yu; A J M Roks
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

9.  Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries.

Authors:  Phillip G Kopf; William B Campbell
Journal:  Endocrinology       Date:  2013-10-03       Impact factor: 4.736

10.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.